2019
1558P Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
Cohen A, Neri B, Adamson B, Scanlon C, Gross C, Meropol N, Miksad R. 1558P Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC). Annals Of Oncology 2019, 30: v642. DOI: 10.1093/annonc/mdz260.080.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerFlatiron HealthOverall survivalBiomarker statusOlder ptsNon-small cell lung cancerAge groupsFred Hutchinson Cancer Research CenterMedian overall survivalNon-squamous histologyCell lung cancerProportional hazards regressionReal-world populationCancer Research CenterAge-related outcomesPDL1 statusLonger OSSimilar OSStage IIIBBaseline characteristicsMetastatic NSCLCPrognostic factorsSmoking statusHazards regressionLung cancer
2004
Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
Murthy VH, Krumholz HM, Gross CP. Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities. JAMA 2004, 291: 2720-2726. PMID: 15187053, DOI: 10.1001/jama.291.22.2720.Peer-Reviewed Original ResearchConceptsCancer trialsCancer clinical trialsClinical trialsTrial participantsEnrollment fractionWhite patientsAge groupsCross-sectional population-based analysisProstate cancer clinical trialsCancer research participationCancer trial participantsColorectal cancer trialsPatients 75 yearsIncident cancer patientsLung cancer trialsPopulation-based analysisRelative risk ratiosAge-based disparitiesYears of ageNational Cancer InstituteLogistic regression modelsLittle recent informationTrial enrolleesYounger patientsPatient group